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Abstract.
Background: Autophagy, a lysosome-mediated self-degradation process of eukaryotic cells, serves as a main route for the
elimination of cellular damage [1–3]. Such damages include aggregated, oxidized or misfolded proteins whose accumulation
can cause various neurodegenerative pathologies, including Huntington’s disease (HD).
Objective: Here we examined whether enhanced autophagic activity can alleviate neurophatological features in a Drosophila
model of HD (the transgenic animals express a human mutant Huntingtin protein with a long polyglutamine repeat, 128Q).
Methods: We have recently identified an autophagy-enhancing small molecule, AUTEN-67 (autophagy enhancer 67), with
potent neuroprotective effects [4]. AUTEN-67 was applied to induce autophagic activity in the HD model used in this study.
Results: We showed that AUTEN-67 treatment interferes with the progressive accumulation of ubiquitinated proteins in the
brain of Drosophila transgenic for the pathological 128Q form of human Huntingtin protein. The compound significantly
improved the climbing ability and moderately extended the mean life span of these flies. Furthermore, brain tissue samples
from human patients diagnosed for HD displayed increased levels of the autophagy substrate SQSTM1/p62 protein, as
compared with controls.
Conclusions: These results imply that AUTEN-67 impedes the progression of neurodegenerative symptoms characterizing
HD, and that autophagy is a promising therapeutic target for treating this pathology. In humans, AUTEN-67 may have the
potential to delay the onset and decrease the severity of HD.
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ABBREVIATIONS
ATG autophagy-related protein
AUTEN-67 autophagy enhancer-67
EDTP egg-derived tyrosine phosphatase
HD Huntington’s disease
AD Alzheimer’s disease
PD Parkinson’s disease
LC3B MAP1LC3B (LC3B), microtubule-
associated protein 1 light
chain 3 beta
PtdIns phosphatidylinositol
RFP red fluorescent protein; Ref(2)
P/SQSTM1/p62, sequestosome
1/hypothetical protein 62 kDa
Vps34 vacuolar protein sorting-
associated protein 34
INTRODUCTION
Huntington’s disease (HD) is a neurodegenerative
genetic disorder caused by an autosomal dominant
mutation in the Huntingtin (HTT) gene [5]. The
encoded protein (HTT) contains a poly-glutamine
(polyQ) tract (an extended CAG trinucleotide repeat
in Htt) that varies in length among individuals. When
the repetition of the polyQ tract passes a critical
threshold (typically over 39) due to a genetic alter-
ation in HTT, it forms an altered, toxic form of HTT.
The intracellular accumulation of mutant HTT can
frequently lead to the loss of certain type of neu-
rons in different parts of the brain, thereby causing
severe changes in personality, cognition and physical
skills (e.g., movement coordination) in the affected
individuals. HD still represents a largely untreatable
pathology.
Autophagy (cellular self-eating) functions as a
major molecular mechanism to degrade superflu-
ous and damaged (e.g., aggregated, oxidized or
misfolded) proteins in eukaryotic cells [1–3]. Dur-
ing the autophagic process, parts of the cytoplasm
are delivered into the lysosomal system contain-
ing acidic hydrolases (proteases, nucleases, lipases
and glycosidases). Besides microautophagy and
chaperone-mediated autophagy, macroautophagy
(hereafter referred to as autophagy) represents a main
form of the autophagic breakdown. It involves the
generation of a double membrane-bound vesicle-
like structure called autophagosome to sequester
the cytoplasmic cargo destined for degradation. The
autophagosome then fuses with a lysosome to form
an autolysosome in which the enzymatic degradation
actually occurs. The relationship between autophagy
and HD is compound. For example, the mutant hHTT
protein is a subject to autophagic degradation [6].
Autophagic receptor proteins, such as SQSTM1/p62,
ALFY and Tollip, have crucial roles in the elimination
of mutant HTT via selective autophagy [7–9], during
which specific cytoplasmic constituents (molecules
or organelles) are labeled for degradation. Mutant
forms of HTT can interfere with the autophagic pro-
cess, including inefficient cargo loading, impaired
movement and maturation of autophagosomes, and
perturbed post-Golgi trafficking to lysosomes (that
results in decreased lysosomal activity) [10–12]. It
is still unclear that during the pathogenesis of HD
which defects dominate [13]. In addition, the wild-
type HTT was recently found to act as a scaffold
protein for selective autophagy [14, 15]. Loss of nor-
mal HTT function may lead to defective autophagy
that contributes to disease pathogenesis.
Formation of the autophagosomal (also called
isolation) membrane requires the class III PtdIns3K
(phosphatidylinositol 3-kinase, formerly called
Vps34 –vacuolar protein sorting-associated protein
34) enzyme complex that converts PtdIns (phos-
phatidylinositol) into PtdIns3P (phosphatidylinositol
3-phosphate) [16]. This biochemical reaction is
reversible; certain myotubularin-related phos-
phatases (MTMRs) antagonize PtdIns3K to generate
PtdIns from PtdIns3P [17]. Indeed, MTMR14, also
called Jumpy in mammals, was demonstrated to
inhibit autophagy in cell cultures [18]. Thus, MTMR
proteins may have evolved to protect the eukaryotic
cells from the injurious hyperactivation of autophagy
under various cellular stress conditions, which can
frequently lead to the loss of the affected cell [19,
20].
By participating in the effective elimination of
cellular damage, autophagy acts a central regula-
tor of the aging process in various animal taxa [3,
21–23]. It is also implicated in the development of
various age-dependent pathologies including cancer,
neurodegenerative diseases, tissue atrophy, dia-
betes, immune deficiency and intracellular infection
caused by microbes [2, 22, 23]. These observa-
tions defined autophagy as a promising therapeutic
target in treating such pathologies [24–27]. To iden-
tify novel autophagy-enhancing drug candidates, we
have recently screened a small molecule library for
inhibitors of human MTMR14/Jumpy [4]. From this
screen, AUTEN-67 (autophagy enhancer-67) was
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isolated. AUTEN-67 potently induces autophagy in
human cell cultures, as well as in model organisms
including Drosophila, zebrafish and mice, signifi-
cantly extends life span in flies, increases the survival
of isolated neurons under both normal and oxida-
tive stress-induced conditions, and improves nesting
behavior in mice expressing an aggregation-prone
human APP (amyloid precursor protein).
In this study we examined the effects of AUTEN-
67 on a Drosophila model of HD (the transgenic
animals express the full length human mutant HTT
protein with a long polyQ tract, 128Q, and dis-
play several neuropathological features observable
in human Huntington pathology). We found that the
molecule significantly increases autophagic activ-
ity in the treated animals, decreases mutant HTT
levels, inhibits the lifelong, progressive accumu-
lation of ubiquitinated proteins in the brain, and
increases the climbing ability and life span of ani-
mals. AUTEN-67 thus impedes the progression of
neurodegenerative symptoms in this HD model. We
also showed that human brain tissue samples exhibit
markedly increased levels of SQSTM1/p62 protein
(which acts as a substrate for autophagy) in patients
diagnosed for HD, as compared with unaffected, age-
matched controls. We suggest that autophagy serves
as a potential therapeutic target for treating HD in
humans.
MATERIALS AND METHODS
Culturing and drug treatment of ﬂies
For maintenance fly stocks were raised on stan-
dard cornmeal-sugar agar medium at 18–25◦C. We
obtained the stocks from Bloomington Drosophila
Stock Center: Appl-Gal4 (BL32040), Ddc-Gal4
(BL7009), UAS-16Q-hHTT/CyO (BL33810), UAS-
128Q-hHTT (BL33808), P{GawB}EDTPDJ694
(pEDTP-Gal4) (BL8176),UAS-myrGFP(BL32199).
The only exception is UAS-mCherry-Atg8a, which
was kindly provided by Ga´bor Juha´sz (Eo¨tvo¨s
University, Hungary), described in [28]. During all
experiments flies were kept at 29◦C. Flies were placed
into vials containing treated medium immediately
after eclosion. AUTEN-67 dissolved in DMSO
(Sigma, D8418) was added to yeast suspension (final
concentration was 50 or 100M), and dropped 65l
to the surface of each vial. For control we used the
same volume DMSO without AUTEN-67. Flies were
transferred into a fresh vial every second day.
Measurement of autophagic structures in the
brain of Drosophila adults
Brains from the heads of 7 day-old adults was
dissected. Preparation of brains was carried out in
PBS (Sigma, P4417) solution. Covering was achieved
in glicerine:PBS (8:2) solution containing Hoechst
33342 (Life Technologies, H-1399) at 10M concen-
tration. Images were captured with Zeiss Axioimager
Z1 upright microscope (with objective Plan-NeoFluar
20 × 0.3 NA) equipped with an ApoTome, and Axio-
Vision 4.82 and ImageJ 1.45 s software were used to
examine and evaluate data. Results are presented as
mean ± SD. Genotype: w∗; UAS-mCherry-Atg8a/+;
Ddc-Gal4/+.
Climbing assay of Drosophila expressing a
human HTT (16Q-hHTT or 128Q-hHTT)
20 female adult flies that express the transgene
under the control of Appl–Gal4 driver were anes-
thetized, and placed in a vertical glass column (length,
25 cm; diameter, 1.5 cm). After 2 hours of recov-
ery period from CO2 exposure, flies were gently
tapped 5 times to the bottom of the column. The
number of flies that reached the line at 21.8 cm
height within 20 and 40 sec was counted. Three
trials of four-six parallel measurements were per-
formed in each experiment. Scores represent the
mean percentage of flies that reached the top line
against the total number tested. Results are presented
as mean ± SD. Genotypes: ApplGal4/+; UAS-16Q-
hHTT/+and Appl-Gal4/+; UAS-128Q-hHTT/+.
Determining the average speed of ﬂies
expressing a human mutant form of HTT, 128Q
10 female adult flies expressing the UAS-128Q-
hHTT transgene under the control of an Appl–Gal4
driver were anesthetized, and placed in a vertical
glass vial (length, 9 cm; diameter, 2.2 cm). After a
45 min recovery period from CO2 exposure, flies
were gently tapped to the bottom of the vial. The
speed of individuals that reached the line at 5 cm
height within 1 min (in the case of 7 and 14-day-old
animals) or 3 min (21-day-old animals) was calcu-
lated. Three parallel experiments and three trials were
executed. Results are presented as mean ± SD of
the average speed (cm/s). Genotypes: ApplGal4/+;
UAS-16Q-hHTT/+and Appl-Gal4/+; UAS-128Q-
hHTT/+.
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Western blot analyses
Protein samples of flies stem from adult heads.
Membranes were probed with anti-Ref(2)P/SQSTM
1/p62 (rabbit, 1:2500, [29]), alpha-Tub84B (mouse,
1:2500, Sigma, T6199), anti-Atg8a (rabbit, 1:2500),
anti-Ubiquitin (mouse, 1:500, Merck, ST1200), anti-
polyQ (mouse 1:1000, Merck, MAB1574), anti-
hHTT (1:1000, Viva Bioscience, VB3130) anti-rabbit
IgG alkaline phosphatase (1:1000, Sigma, A3687)
and anti-mouse IgG alkaline phosphatase (1:1000,
Sigma, A8438) and developed by NBT-BCIP solu-
tion (Sigma, 72091). ImageJ 1.45 s software was used
to examine and evaluate data. Results are presented
as mean ± SD. Genotypes: ApplGal4/+; UAS-16Q-
hHTT/+and Appl-Gal4/+; UAS-128Q-hHTT/+.
Immunohistochemistry on Drosophila brain
samples
The cuticles of adult heads were opened in PBS
and fixed in PBS containing 4% formaldehyde
for overnight at 4◦C. After fixation, samples were
washed in PBST (PBS containing 0.3% Triton X-
100) for 20 min by three times. Then, samples were
incubated in blocking solution (PBST containing
5% goat serum) for an hour. Samples were sub-
sequently incubated overnight at 4◦C in blocking
solution containing the primary antibodies. After
incubation with the given primary antibody, samples
were washed in 5xNaCl PBST for 20 min, then in
PBST for 20 min. It was followed by the blocking
solution for 30 min. Samples were then incubated
in blocking solution containing the given secondary
antibodies for 60 min. It was followed by wash-
ing steps as had been carried out after incubation
with primary antibodies. For staining nuclei, we used
Hoechst solution (1 mM was dissolved in PBS, 1:200)
for 6 min. Then, samples were washed in PBST for
20 min, and in PBS for another 20 min. The dissec-
tion of stained brain sample was performed in PBS,
and for mounting we used ProLong Gold antifade
reagent (Molecular Probes, P36934). Every step
was executed at room temperature, otherwise indi-
cated. The following primary antibodies were used:
Anti-Ref(P)2/p62 (rabbit, 1:200 [29], anti-polyQ
(1:100 Merck, MAB1574). For nuclear staining,
Hoechst 33342 (0.1 mg/ml, Molecular Probes) dye
was used. Anti-Rabbit Alexa Fluor 488 (Life Tech-
nologies, A11008) and anti-Mouse Texas Red (Life
Technologies, T862) in 1:500 were used as sec-
ondary antibodies. Images were captured with a Zeiss
Axioimager Z1 upright microscope (with objective
Plan-NeoFluar 20 × 0.3 NA and Plan-Apochromat
63 × 1,4 NA) equipped with an ApoTome, and
AxioVision 4.82 and ImageJ 1.45 s software were
used to examine and evaluate data. Results are
presented as mean ± SD. Genotypes: ApplGal4/+;
UAS-16Q-hHTT/+and Appl-Gal4/+; UAS-128Q-
hHTT/+.
Life span measurements
To analyze the life span, adult females were
selected. The drug treatment was performed as
described above. Flies were transferred into fresh
medium containing vials every second day. The num-
ber of dead animals was counted daily. Measu-
rements were carried out with eight parallels, with
20–30 flies in each. Mean life spans are presented
as mean ± SEM. Genotypes: ApplGal4/+; UAS-16Q-
hHTT/+and Appl-Gal4/+; UAS-128Q-hHTT/+.
Brain tissue samples
Paraffin-embedded human brain tissue samples
from parietal and temporal cortices (or subfields of
these areas) of normally aged, non-affected (control)
subjects and HD-affected individuals were obtained
from a brain tissue bank. Samples were collected
from donors for or from whom a written informed
consent for a brain autopsy, the use of tissue samples
and permission for anonymous use of clinical infor-
mation was obtained. Control samples were obtained
from clinical patients having no central nervous sys-
tem (CNS) medication before death and showed no
sign of disease.
Immunohistochemistry on human brain tissue
samples
Paraffin-embedded tissue sections were deparaf-
finized, rehydrated and used in light microscopic
immunohistochemistry. For identification of neurons
and demonstration of the presence of ubiquiti-
nated proteins in the autophagy pathway, anti-NeuN
and anti-p62 antibodies were used in consecutive
sections. NeuN and SQSTM1/p62 immunohisto-
chemistry was performed as described [30]. For
antigen recovery, deparaffinized sections were boiled
in 0.01 M citrate-buffer solution (pH 6.0) in a
microwave oven for 2 min (set at 900 watts). After
blocking the endogenous peroxidase in 0.05 M PBS
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containing 3% H2O2, sections were washed for
3–5 min in 0.05 M PBS (pH 7.5) at RT. Tissue
sections were next permeabilized, and the back-
ground binding of antibodies was reduced in a
blocking solution (0.1 M PBS containing 5% nor-
mal goat serum, 1% BSA, 0.05% Triton X-15 100)
for 30 min at 37◦C. Sections were covered with the
above solution containing either mouse anti-NeuN
primary antibody (1:500 final dilution; Chemicon,
Billerica, MA, USA) or mouse anti-p62 primary
antibody (1:150 final dilution; Abcam, Cambridge,
MA, USA) at 4◦C for overnight. After incuba-
tion with the primary antibodies, sections were
washed for 4 × 5 min in 0.05 TBS (pH 7.5) at RT.
Sections were then treated with biotinylated anti-
mouse IgG secondary antibody (1:200 final dilution;
Amersham Biosciences, Little Chalfont, Bucking-
hamshire, England) in a blocking solution (where
Triton X-100 was omitted) for 5 hours at RT. After
several washes (4 × 5 min), biotinylated streptavidin-
peroxidase tertiary antibody (1:200 final dilution;
Amersham) in a blocking solution (without Triton
X-100) was applied to the sections overnight at 4◦C.
Sections were washed again in 0.05 M TBS (pH
7.5) for 4 × 5 min at RT, and processed for per-
oxidase enzyme histochemistry using Sigma Fast
DAB Tablet (Sigma, St. Louis, MO, USA) accord-
ing to the manufacturer’s protocol. Sections were
washed for 3 × 5 min in 0.05 M TBS (pH 7.5) at RT,
washed in distilled water for 1 min, dehydrated in a
series of ethanol solutions, covered with DPX mount-
ing medium (Fluka, 30 Buchs, Switzerland), and
coverslipped. Quantitative analysis of immunohisto-
chemically processed tissue sections was performed
as described [31]. NeuN- and SQSTM1/p62-positive
cells were counted with the use of the computer
program ImageJ (version 1.47; developed by W. Ras-
band at the U.S. National Institutes of Health, and
available from internet at http://rsb.info.nih.gov/ij).
After calibration and setting the appropriate scale,
the digital image file was opened and the back-
ground was subtracted by setting the “rolling ball
radius” to 50 pixels. Overlapping objects in the
resulting binary images were then separated via the
menu command “Process/Binary/Watershed” [32].
For counting NeuN-positive cells, “Analyze/Analyze
Particles” menus were selected, size (56–2500 m) and
circularity (0.5–1.0) values were chosen, then the
output was copied to a Microsoft Excel spreadsheet
(Microsoft Corp., Redmond, WA, USA) for statistical
analysis. SQSTM1/p62-positive cells were counted
manually.
Statistics
Lilliefors test were used to know that the dis-
tribution of samples examined is normal or not. If
it was normal, F test was performed to compare
two variances. If the variances were equal, two-
sample Student’s t-test was used. If the variances
were unequal we used Welch-test (t-test for unequal
variances). If the distribution of a sample is not
normal, Mann-Whitney U test was performed. We
used the software MatLab 7.12.0 (R2011a). For life
span analyses we used SPSS 17 software to perform
statistical analysis. p values for comparing Kaplan-
Meyer survival curves between two groups were
determined by log-rank (Mantel-Cox) tests, andpval-
ues for comparing mean life spans were determined
by Mann-Whitney Test. Bonferroni corrections were
carried out.
RESULTS
AUTEN-67 enhances autophagy in the brain of
Drosophila expressing 128Q hHTT
A transgenic Drosophila strain containing a UAS-
driven full-length human Huntingtin protein with a
large poly-glutamine expansion in the N-terminus
(128Q-hHTT) serves as a tractable in vivo model
system for studying the pathology of HD [33, 34].
Flies transgenic for 16Q-hHTT (containing a rel-
atively short poly-glutamine repeat) were used as
control. In the transgenic 128Q-hHTT animals (in
which c164-Gal4 was used as a driver), the progres-
sive accumulation of toxic proteins in certain types of
neurons (motoneurons) can cause massive levels of
cell death, which is associated with various neurobio-
logical abnormalities. We aimed to assess the effects
of autophagy on the progression of neurodegenera-
tive symptoms in a similar Drosophila model of HD.
In this particular model, the full length 128Q-hHTT
transgene is driven by Appl-Gal4/+ that is active in
all neurons. Characterization of the strain revealed a
pleiotropic HD-like phenotype including a short life
span and reduced climbing ability (see later in the
Results section), but not lowered flight performance
(Supplementary Figure S1). We treatedAppl-Gal4/+;
UAS-128Q-hHTT/+transgenic flies with AUTEN-67,
a potent enhancer of autophagy [4]. As shown pre-
viously, AUTEN-67 increases autophagic flux in the
Drosophila fat body [4]. Consistent with these data,
we found a significant increase in the number of
autophagic structures labeled by a mCherry-Atg8a
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reporter (Atg denotes an autophagy-related protein)
in brain samples of treated animals, as compared
with those from untreated controls (Fig. 1A, A’).
Atg8a is a ubiquitin-like key autophagy protein
that is conjugated to the forming isolation mem-
brane; the mCherry-Atg8a reporter readily marks
autophagosomes and autolysosomes [28, 35]. How-
ever, an elevated number of Atg8a-specific structures
is not necessarily indicative of enhanced autophagic
activity. It can even indicate defects in the process
(e.g., autophagosome formation is not followed by
autophagosome-lysosome fusion). To confirm that
AUTEN-67 indeed triggers the autophagic degrada-
tion in the transgenic flies, we measured Ref(2)P
protein levels, and compared with those found
in untreated animals. Ref(2)P is the Drosophila
ortholog of human SQSTM1 (sequestosome 1)/p62
protein serving as a substrate for autophagic degra-
dation; its intracellular level inversely correlates with
autophagic activity [36, 37]. According to our West-
ern blot (Wb) analysis, Ref(2)P/SQSTM1/p62 levels
were significantly lower in AUTEN-67-treated ani-
mals than in untreated (DMSO) controls in both
16Q-hHTT and 128Q-hHTT transgenic backgrounds
(Fig. 1B, B’). Moreover, Atg8a-II (the membrane-
bound form of Atg8a) levels were decreased in
the treated animals, further suggesting an elevated
autophagic activity (flux) as a result of adding
AUTEN-67 (Atg8a also becomes degraded during
the autophagic process) (Fig. 1B, B’; Supplementary
Figure S1). We also found that EDTP (egg-derived
tyrosine phosphatase), the fly ortholog of human
MTMR14/Jumpy gene, is strongly expressed in the
Drosophila brain (Fig. 1C, C’). These data explain
why AUTEN-67 could influence autophagic activ-
ity in this tissue (the molecule enhances autophagy
through inhibiting MTMR14/Jumpy; [4]). Together,
AUTEN-67 potently increased autophagic flux in
UAS-128Q-hHTT transgenic flies (Fig. 1).
The Wb analysis also showed that relative levels
of Ref(2)P/SQSTM1/p62 proteins are less in 128Q-
hHTT than in 16Q-hHTT animals (Fig. 1B, B’). This
suggests that basal autophagic activity is significantly
higher in 128Q-hHTT flies than in those expressing
non-toxic 16Q-hHTT (Fig. 1B, B’). The pathologi-
cal 128Q-hHTT protein (proteotoxicity) may trigger
a general stress response that involves autophagy,
explaining why the autophagic process is increased
in transgenic flies expressing the toxic form.
Alternatively, in 128Q-hHTT samples the major-
ity of Ref(2)P/SQSTM1/p62 may be present in
insoluble forms (e.g., associated with inclusion
bodies/cytoplasmic aggregates), thereby remaining
undetectable by the protein isolation method (Wb)
used in this study. Indeed, in cell culture and
Drosophila models of HD the mutant 128Q-hHTT
forms protein inclusions in the cytoplasm or in the
nucleus, and SQSTM1/p62 strongly associates with
these structures [7, 38]. This could explain why sol-
uble Ref(2)P/SQSTM1/p62 levels are lower in 128Q
than in 16Q samples on the Wb shown in Fig. 1B.
To address this issue we performed immunohis-
tochemical staining with anti-Ref(2)P antibody (this
method is capable of detecting both soluble and
insoluble Ref(2)P/SQSTM1/p62 proteins) (Fig. 2A,
A’). The analysis revealed that Ref(2)P/SQSTM1/p62
levels are much higher in the brain of animals
transgenic for the mutant 128Q-hHTT, as com-
pared with 16Q-hHTT samples (rows 1 vs. 3 in
Fig. 2A). Most of the Ref(2)P/SQSTM1/p62 pro-
teins localized to inclusion-like structures (row
3 in Fig. 2A). Treatment with the autophagy-
enhancing AUTEN-67 markedly reduced the amount
of Ref(2)P/SQSTM1/p62 in 128Q-hHTT samples.
Based on these results we conclude that the Western
blotting shown in Fig. 1B demonstrates only soluble
Ref(2)P/SQSTM1/p62 proteins.
AUTEN-67 treatment reduces toxic polyQ/
128QhHTT protein levels
We next asked whether enhanced autophagic activ-
ity triggered by AUTEN-67 treatment can reduce
toxic 128Q-hHTT levels in brain samples of trans-
genic flies. An immunohistochemical staining with
anti-polyQ antibody revealed a non-significant trend
towards a decrease in the amount of 128Q-hHTT
proteins in the treated animals, as compared with
untreated controls (Fig. 2B, B’). An intriguing aspect
of these results is that 128Q-hHTT predominantly
accumulated in protein inclusions (red foci on the last
fluorescent image in Fig. 2B), rather than exhibiting
a diffuse staining pattern. 128Q-hHTT-positive struc-
tures were surrounded by Ref(2)P/SQSTM1/p62
proteins, suggesting that the aggregates are subject
to elimination by selective autophagy.
Using anti-polyQ and anti-hHTT antibodies, we
also performed a Wb analysis to quantify relative
128Q-hHTT levels in brain samples (Fig. 2C, C’).
A significant decrease in 128Q-hHTT accumulation
was evident from this set of experiments. Taken
together, AUTEN-67 administration reduces the level
of toxic 128Q-hHTT proteins in this animal model of
HD.
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Fig. 1. AUTEN-67 enhances autophagy in the brain of a Drosophila model of Huntington’s disease. A, AUTEN-67 elevates the number of
Atg8a-positive structures (autophagosomes and autolysosomes) in brain samples in a concentration-dependent manner. Left panels: mCherry-
Atg8a reporter indicates autophagic structures (red foci); middle panels: Hoechst staining indicates nuclei; right panels: Merged images.
Fluorescent images. A’, Quantification of mCherry-Atg8a-positive structures in brain samples from untreated (control) vs. AUTEN-67-
treated animals. Bars represent mean ± S.D, ∗p < 0.05; Welch-test (t-test for unequal variances) (n = 7, p = 0.0297) and Mann-Whitney U-test
(n = 13, p = 0.0236). B, A representative Western blot (Wb) showing that AUTEN-67 decreases soluble Ref(2)P/SQSTM1/p62 protein levels
in the head of animals expressing a human normal (16Q) or mutant (128Q) Huntingtin protein (hHTT). This suggests that the small molecule
increases autophagic degradation in these transgenic flies. Alpha-Tubulin84B (Tub84B) serves as an internal control. Unconjugated (I)
and conjugated (II) forms of Atg8a (a key autophagic protein) are also shown. Analyses were carried out with 7 day-old adult flies. “hHTT”
denotes human Huntingtin protein. B’, Quantification of soluble Ref(2)P/SQSTM1/p62 protein levels. In both 16Q and 128Q samples,
AUTEN-67 treatment significantly reduced Ref(2)P/SQSTM1/p62 levels. Statistics were calculated from 4 independent Wb experiments
(n = 4). Bars represent mean ± SD, ∗p < 0.05, two-sample Student’s t-test [16Q DMSO – 16Q AUTEN-67 (100M) p = 0.01467; 128Q
DMSO – 128Q AUTEN-67 (100M) p = 0.03394]. C, EDTP/MTMR14/Jumpy promoter is highly active in the Drosophila brain. Animals
of w1118 ; P{GawB}EDTPDJ694 (pEDTP-Gal4)/UAS-myrGFP were examined. C’, The corresponding Hoechst staining indicates nuclei.
AUTEN-67 retards the accumulation of
ubiquitinated proteins in the aging brain
Ubiquitination of damaged proteins is a general
feature of all aging cells [39]. Thus, we decided
to monitor ubiquitinated protein accumulation in
the brain of AUTEN-67-treated versus untreated
control animals. Staining of brain samples with a
Ubiquitin-specific antibody revealed that AUTEN-67
significantly reduces the relative amount of dam-
aged proteins at the age of 21-day-old adulthood
(Fig. 3). This phenomenon was evident not only in
animals expressing the mutant 128Q-hHTT protein,
but also in those expressing its non-toxic version
(16Q-hHTT). It is intriguing that relative levels of
ubiquitinated proteins were lower in animals that
express the pathological 128Q-hHTT protein (Fig. 3).
This is in good accordance with our previous results
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Fig. 3. AUTEN-67 retards the accumulation of soluble ubiquitinated proteins in the head of a Drosophila model of HD. A, A representative
Western blot (Wb) showing the accumulation of (damaged) ubiquitinated proteins in head samples of animals at adult age of 18–21 days.
Proteins were visualized by anti-Ubiquitin antibody staining. The compound significantly lowered relative levels of soluble ubiqitinated
proteins in animals expressing normal (16Q) and mutant (128Q) hHTT. “hHTT” denotes human Huntingtin protein. A’, Quantification of
relative soluble ubiquitinated protein levels from three independent Wb experiments (n = 3). Bars indicate mean ± SD, ∗p < 0.05, two-sample
Student’s t-test [16Q DMSO – 16Q AUTEN-67 (100M), p = 0.03178; 128Q DMSO – 128Q AUTEN-67 (100M), p = 0.04472]. Similar to
Ref(2)P/SQSTM1/p62 protein localization (see Figs. 1B and 2A), a significant portion of ubiquitinated proteins may accumulate in insoluble
forms in 128Q samples, and thereby is not detectable by Wb analysis as performed in this study.
showing decreased Ref(2)P/SQSTM1/p62 protein
levels in animals transgenic for 128Q-hHTT, rela-
tive to those expressing 16Q-hHTT (Fig. 1B, B’).
Ubiquitinated (damaged) proteins can also associate
with protein inclusions in aged or HD-affected brain
tissues [37, 40]. So, only the soluble fraction of
ubiquitinated proteins may be detectable by West-
ern blotting performed in this study. Nevertheless,
AUTEN-67 hampered the age-dependent accumula-
tion of ubiquitinated proteins in neurons of this HD
model.
AUTEN-67 treatment improves climbing ability
in ﬂies expressing 128QhHTT
HD is a neurodegenerative disorder that affects
among others muscle coordination [5]. This knowl-
edge prompted us to investigate the capacity of HD
model animals to climb up on the wall of glass vials in
the presence or absence of AUTEN-67. This climbing
assay actually exploits the negative geotaxis behav-
ior of Drosophila. When animals transgenic for the
non-pathological (16Q) hHTT protein were collected
Fig. 2. Immunohistochemical detection of Ref(2)P/SQSTM1/p62 and polyQ (mutant hHTT) proteins in flies expressing normal (Q16)
and mutant (128Q) hHTT. A, Anti-Ref(2)P/SQSTM1/p62 antibody staining (green) indicates both soluble and insoluble protein levels in
Drosophila brain samples. Total amounts of Ref(2)P/SQSTM1/p62 are much higher in samples expressing the mutant (128Q) hHTT protein
(1 vs. 3 row). However, in 128Q samples the majority of Ref(2)P/SQSTM1/p62 localizes to large foci that are likely to correspond to inclusion
bodies/cytoplasmic aggregates (i.e., exists in insoluble forms). AUTEN-67 treatment significantly lowered Ref(2)P/SQSTM1/p62 levels in
128Q samples (3-4 rows). In 16Q samples, Ref(2)P/SQSTM1/p62 levels are relatively low (only a faint staining is detectable, occasionally
small foci can also be found; 1-2 rows). Hoechst staining (blue) indicates nuclei. Experiments were performed on 18–21 day-old adult flies.
“hHTT” denotes human Huntingtin protein. A’, Quantification of (total) Ref(2)P/SQSTM1/p62 levels in immunohistochemically stained
samples. Bars represent mean ± SD, ∗p < 0.05, two-sample Student’s t-test or Welch-test. [16Q – DMSO vs. 16Q – AUTEN-67 (100M),
p = 0.1019 (two-sample Student’s t-test); 128Q – DMSO vs. 128Q – AUTEN-67 (100M), p = 0.015 (Welch-test)]. “ns” denotes not
significant. Analyses were carried out with 18–21 day-old adult flies. B, Anti-polyQ (red) and anti-Ref(2)P/SQSTM1/p62 (green) antibody
staining on 128Q brain samples. AUTEN-67 treatment reduced both toxic 128Q hHTT and autophagy substrate Ref(2)P/SQSTM1/p62 protein
levels. The large figure (at the bottom) is an enlargement of the area indicated by a white dashed line in the first panel. Ref(2)P/SQSTM1/p62
proteins (green) localize around hHTT aggregates (red). White arrows point to the periphery of such aggregates which is positive for green
labeling. Hoechst staining (blue) indicates nuclei. B’, PolyQ (which corresponds to mutant hHTT) and Ref(2)P/SQSTM1/p62 proteins
largely colocalize, and their levels are reduced upon AUTEN-67 treatment. Area ratio of polyQ- and Ref(2)P/SQSTM1/p62-positive cells
are not significantly different between treated or untreated samples. Bars represent mean ± SD, p values indicate tendentious differences
(for polyQ: p = 0.2045; for Ref(2)P/SQSTM1/p62: p = 0.1798), two-sample Student’s t-test. C, Representative Western blots (Wb) showing
polyQ/mutant hHTT levels in Drosophila head samples (performed by anti-polyQ antibody staining and anti-hHTT antibody staining).
AUTEN-67 reduced polyQ/128Q hHTT levels (the corresponding lanes are indicated by black arrows). Tub84B was used as a control.
C’, Quantification of mutant hHTT/polyQ protein levels were calculated from 4-4 independent assays (n = 4). Bars represent mean ± SD,
∗p < 0.05, two-sample Student’s t-test (for mutant hHTT, p = 0.03841; for polyQ, p = 0.01109).
Un
co
rre
cte
d A
uth
or
 P
ro
of
10 V. Billes et al. / Autophagy is Implicated in Huntington’s Disease
Fig. 4. AUTEN-67 improves climbing ability in flies expressing a human mutant Huntingtin protein (128Q). A, Climbing assay used in
this study. 25 cm long glass vials were used to monitor the ability of animals to climb on the wall of test tubes. Left: At the starting point
(0 sec) animals were shaken down at the bottom of the glass vial. After 20 sec, the vast majority of the animals climbed up to the top of the
vial (negative geotaxis). Middle: Animals expressing the mutant hHTT (128Q) are unable to climb up on the wall of the glass vial. Right:
AUTEN-67 markedly improved the ability of animals transgenic for 128Q-hHTT to climb up to the top of the tube. Orange bars indicate the
regions where the animals accumulated. “hHTT” denotes human Huntingtin protein. B, AUTEN-67 significantly restored climbing ability
in flies expressing 128Q hHTT. Testing was performed at 20 sec after shaking down. C, AUTEN-67 also restores climbing ability when
animals were tested at 40 sec after shaking down. D, AUTEN-67 increased the speed at which the animals climb up to the top of vials.
Adults at different ages (7, 14 and 21 days) were assayed. In panels B to D, bars indicate mean ± SD, ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001,
Mann-Whitney U-test.
at the bottom of test tubes (25 cm in length) by tap-
ping, they could climb up to the top within around
40 seconds (Fig. 4A-C). In contrast, animals express-
ing the mutant 128Q-hHTT protein were largely
unable to climb up on the wall within the same
timeframe. The addition of AUTEN-67 to the
growth medium restored the climbing ability of
affected (128Q-hHTT) flies to nearly normal levels
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Fig. 5. AUTEN-67 extends the life span of Drosophila expressing the human normal (16Q) and a mutant (128Q) Huntingtin protein. A,
Difference in life span between untreated (DMSO) and treated (100M AUTEN-67) animals expressing the human normal (16Q) and
mutant (128Q) Huntingtin protein is significant: p < 0.001, long-rank (Mantel-Cox) test. A’, Mean life span data from panel A. Bars indicate
mean ± SEM, ∗p < 0.05; ∗∗p < 0.01, ∗∗∗p < 0.001, Mann-Whitney U-test.
(Fig. 4A-C). In the presence of AUTEN-67, animals
transgenic for 128Q-hHTT could reach the top of
the vials when they were at the age of 7- and 14-
day-old adulthood. This positive effect of AUTEN-67
on the climbing capacity of HD model animals was
more obvious when the assay was performed for
20 seconds only (Fig. 4B, C). We also tested the
speed at which 128Q-hHTT animals climb up on the
glass wall at different (7-, 14- and 21-day-old) adult
ages. The results demonstrated that animals climb up
faster on the wall when AUTEN-67 is added to the
medium (Fig. 4D). Thus, elevated autophagic activity
significantly increases the climbing capacity of flies
representing a HD model.
AUTEN-67 extends life span in Drosophila
expressing 16Q or 128Q hHTT proteins
If the severity of neurodegenerative symptoms
in this Drosophila HD model is attenuated by the
administration of AUTEN-67, one can ask whether
the compound delays the deterioration of affected
animals. To this end we measured the life span of
untreated versus AUTEN-67-treated animals trans-
genic for 128Q-hHTT. We found that in the absence of
AUTEN-67, 128Q-hHTT animals live significantly
shorter than 16Q-hHTT ones (i.e., 128Q-hHTT-
mediated proteotoxicity markedly decreased the
ability of animals to survive), and that AUTEN-
67 increases, although only moderately, longevity
in 128Q-hHTT animals (Fig. 5 and Supplementary
Table S1). Based on these data we conclude that
pharmacologically-enhanced autophagy can extend
the life span of animals expressing the pathological
128Q-hHTT protein.
SQSTM1/p62 accumulates in postmortem human
brain samples affected with HD
Finally, we also examined the accumulation of
SQSTM1/p62 proteins in postmortem human brain
tissue samples obtained from patients that were
diagnosed for HD or as non-affected, age-matched
controls. Frontal and parietal lobe brain tissue
samples were immunohistochemically stained with
a SQSTM1/p62-specific antibody (see the Mate-
rials and Methods). Intracellular localization of
SQSTM1/p62 appeared to be both cytoplasmic and
nuclear. Similar to data we obtained from Drosophila
(Fig. 2A, A’), the number of SQSTM1/p62-positive
cells was significantly higher in the disease-affected
samples than in control ones (Fig. 6A, A’). It is worth-
while to note that the average number of neurons
was not significantly different between the control
and affected samples (Fig. 6A). The cytoplasmic dif-
fuse staining was also elevated in the disease-affected
samples. This finding is indicative of decreased
autophagy in the brain of HD patients. Thus, these
results suggest that defects in autophagy contribute
to the development of HD.
DISCUSSION
Autophagy functions as a major cellular process to
degrade aggregation-prone proteins in the cytoplasm
[2, 3, 24]. Defects in autophagic degradation have
indeed been widely implicated in the development
of various neurodegenerative conditions [13, 24, 25].
In the present study we examined the effects of
enhanced autophagic activity on the pathogenesis of
HD in a Drosophila model expressing the full length
human mutant hHTT protein (128Q) in all neurons.
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Fig. 6. Postmortem brain samples from patients diagnosed for HD display increased levels of SQSTM1/p62. A, Light microscopy shows
SQSTM1/p62 accumulation in neurons from frontal parts of human brain tissues (SQSTM1/p62 serves as an autophagy substrate, so its
presence may be indicative for lowered or absent autophagic activity). Postmortem samples were prepared by using anti-SQSTM1/p62
antibody staining. Age-matched, unaffected controls (left panels) and affected (diagnosed for HD; right panels) samples are compared.
White scale bars are indicated. At the bottom panel, dashed white and black framings show a SQSTM1/p62-positive and a SQSTM1/p62-
negative neuron, respectively. A’, Quantification of neurons positive for SQSTM1/p62 antibody staining in control vs. HD samples. Bars
indicate mean ± SD. For statistics, ∗p < 0.05; paired Student t-test. Note that there was no statistically significant difference in the number of
neurons found in control versus disease-affected samples. Average number of neurons/mm2: 11157.7 ± 25.5 control frontal, 9782.2 ± 11.6
control parietal; 11122.6 ± 10.9 HD frontal, 9435.05 ± 26.8 HD parietal. In panels A and A’: C indicates control, “HD” denotes Huntington’s
disease.
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To modulate autophagy, we used a recently identified
autophagy-enhancing small molecule, AUTEN-67
[4]. We revealed here that AUTEN-67 increases
autophagic flux and reduces (128Q) hHTT protein
levels in the brain of this Drosophila HD model
(Fig. 1A-B’), attenuates the age-dependent accumu-
lation of damaged (polyubiquitinated) proteins in
this HD model (Fig. 3), significantly improves the
climbing capacity (i.e., motor activity) of the treated
animals (Fig. 4), and moderately extends the survival
of flies transgenic for 128QhHTT (Fig. 5 and Sup-
plementary Table S1). Although the latter effect is
relatively small, but appears to be remarkable in light
of the fact that the autophagy-inducing rapamycin-
ester CCI-779 has no significant effect on the survival
of a mouse HD model [41]. These data imply that
activation of autophagy by pharmacological means
hampers the progression of neurodegenerative symp-
toms triggered by the expression of the pathological
full length 128Q-hHTT protein. Thus, AUTEN-67,
which has potent neuroprotective effects, but no
known undesired side-effect [4], serves as a promis-
ing drug candidate for treating HD.
AUTEN-67 appears to be capable of pene-
trating through the blood-brain barrier, and to
specifically inhibit the phosphatase activity of
hMTMR14/Jumpy [4], a negative regulator of
autophagic membrane formation [18]. We observed
that EDTP/hMTMR14/Jumpy is expressed in the
Drosophila brain (Fig. 1C, C’) and thus, AUTEN-67
may modulate autophagy induction in neurons.
Although mutations in certain MTMR genes can lead
to human disorders such as myotubular myopathy
and Charcot-Marie-Tooth peripheral neuropathy
[17, 42], until now there was no study reporting
the involvement of hMTMR14/Jumpy deficiency
in any neuropathological condition. In addition,
hMTMR14/Jumpy is also readily detectable in
mammalian brain tissues (see at the Expression Atlas;
https://www.ebi.ac.uk/gxa/experiments/E-MTAB-
2798? specific=on&queryFactorType=ORGANISM
PART&queryFactorValues=&geneQuery=mtmr14
&exactMatch=true). Based on these results, we
propose that AUTEN-67 has the potential to be
used to enhance autophagic activity via inhibiting
hMTMR14/Jumpy in the human central nervous
system.
An intriguing result we obtained in this study is that
Ref(2)P/SQSTM1/p62 protein levels in the brain of
Drosophila expressing the pathological 128Q-hHTT
protein are significantly lower than in animals trans-
genic for non-toxic 16Q-hHTT (Figs. 1B, B’, 3A, A’).
In good accordance with this observation, relative
levels of ubiquitinated proteins in the brain were
also decreased in 128Q-hHTT transgenic animals,
as compared with controls (16Q-hHTT) (Fig. 3).
To explain these results, we argue that a significant
amount of Ref(2)P/SQSTM1/p62 and ubiquitinated
proteins may localize to protein aggregates. Thus,
only a fraction of these proteins should present in
a soluble form that is detectable by Western blot-
ting as performed here. To support experimentally
this assumption, a Ref(2)P/SQSTM1/p62-specific
antibody staining was performed on brain tissue
samples (Fig. 2A, A’). This immunohistochemical
labeling could detect both soluble and insoluble
(inclusion-associated) Ref(2)P/SQSTM1/p62, and
showed much higher levels of the protein in 128Q-
hHTT than in 16Q-hHTT brain samples. In addition,
it may explain why the level of ubiquitinated proteins
is lower in 128Q-hHTT than in 16Q-hHTT samples,
because protein inclusions in aged or HD-affected
brains also contain ubiquitin [37, 40]. Never-
theless, AUTEN-67 treatment markedly enhanced
autophagic activity and reduced the accumulation of
damaged proteins in brain samples prepared from
both transgenic strains (Figs. 1B, B’, 2A-B’ and
3A, A’). Postmortem human brain tissue samples
from patients diagnosed for HD also displayed highly
increased levels of Ref(2)P/SQSTM1/p62, relative to
age-matched, unaffected controls (Fig. 6A, A’). As
Ref(2)P/SQSTM1/p62 acts as a substrate in selective
autophagy, one can speculate that in humans either
mechanistic defects in autophagy and/or altered Atg
gene expression are involved in HD pathogenesis, and
accumulation of pathological hHTT proteins inter-
feres with the autophagic process [10–12]. Therefore,
our results presented here point to autophagy as a
promising therapeutic target in treating HD. Phar-
macological agents that enhance autophagic flux in
neurons may be used effectively in treating HD-
related symptoms, and AUTEN-67 represents such
a drug candidate.
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